Core Insights - BioPorto A/S is sponsoring conferences focused on pediatric solid organ transplants and critical care nephrology, presenting new NGAL scientific data that enhances the identification and management of Acute Kidney Injury (AKI) in patients [1][2]. Group 1: Conference Participation - The International Pediatric Transplant Association (IPTA) held a biennial event in Berlin with over 500 participants, addressing AKI concerns in pediatric patients through various sessions [2]. - Dr. Kyle Merrill and Dr. June Oh presented a special session on NGAL usage, attended by over 100 participants, highlighting its application in patient cases [2]. - The 5th International Symposium on AKI in Children commenced on September 26 in Cincinnati, aiming for scientific collaboration across pediatric communities [2]. Group 2: Research and Publications - Multiple abstracts and posters will feature NGAL research from academic clinicians globally, with a notable publication discussing NGAL's role in predicting kidney support therapy duration in critically ill children [3]. - The research on NGAL is significant as there is currently no standard of care in this area, indicating potential future diagnostic applications [3]. Group 3: Company Information - BioPorto has facilities in Copenhagen and Boston, and its shares are listed on the Nasdaq Copenhagen stock exchange [6].

Core Insights - BioPorto is actively participating in the Association for Diagnostics & Laboratory Medicine meeting, focusing on NGAL and Acute Kidney Injury (AKI) [1][4] - The conference highlights the importance of early detection of AKI, particularly in pediatric populations, using NGAL as a promising biomarker [2][4] - BioPorto's ProNephro AKI™ (NGAL) is FDA cleared for risk stratification of ICU patients aged 3 months to 21 years for moderate to severe AKI [4][11] Industry Focus - AKI remains a critical topic in laboratory medicine, especially with changes in eGFR calculations and the transition from AKI to Chronic Kidney Disease (CKD) [2] - The conference includes special sessions on next-generation biomarkers for early prediction and diagnosis of AKI, emphasizing the need for innovative diagnostic tools [3][2] - Ongoing interest in AKI is expected to continue into 2025 and 2026, driven by the KDIGO project to update AKI guidelines [6] Company Initiatives - BioPorto is promoting its NGAL tests to lab directors and clinical managers at the conference, aiming to enhance awareness and adoption of its products [4][7] - The company is engaging with worldwide partners to review collaborations and the business impact of its FDA cleared products [5] - BioPorto's focus on actionable biomarkers aims to improve clinical outcomes and patient management in AKI [10][11]